The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J01 | Antibacterials for systemic use | |
3
|
J01M | Quinolone antibacterials | |
4
|
J01MA | Fluoroquinolones | |
5
|
J01MA01 | Ofloxacin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 0.4 g | |
| PAREN | Parenteral | 0.4 g |
| Active Ingredient |
|---|
|
Ofloxacin is a quinolone-carboxylic acid derivative with a wide range of antibacterial activity against both Gram-negative and Gram-positive organisms. The primary mode of action of the quinolones is the specific inhibition of bacterial DNA gyrase. This enzyme is required for DNA replication, transcription, repair and recombination. |
| Document | Type | Information Source | |
|---|---|---|---|
| MEDOFLOXINE Film-coated tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| OFLOXIN Film-coated tablet | MPI, EU: SmPC | Υπουργείο Υγείας (CY) | |
| TARIVID Solution for infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.